DXCM - DexCom up 4% in after-hours trading on quarterly bottom line beat

• DexCom ( NASDAQ: DXCM ) is up 4% in after-hours trading after the continuous glucose monitor company saw its Q4 2022 financial results beat on the bottom line .
• Non-GAAP net income $136.3M ($0.34 per diluted share) for the quarter compared to a net loss of $2.4M  ($0.01) Q4 2021.
• U.S. revenue grew 17%; international revenue was up 15% year over year. Overall revenue grew 17% to $815.2M in the quarter.
• In addition, DexCom ( DXCM ) reiterated earlier 2023 guidance, including revenue of $3.35B-$3.49B vs $3.46B consensus, representing 15%-20% growth.
• The company ended the quarter with cash and cash equivalents of $642.3M, a 39% drop from the year-ago period.
• Read why Seeking Alpha contributor LD Investments rates DexCom ( DXCM ) a hold.

For further details see: